Drugs / GAMMAGARD S/D
last change Sep 2003 re-read 2 minutes ago

GAMMAGARD S/D

Developed for
agammaglobulinemia
Investigated by
Baxalta now part of Shire

Trials 1 · a red edge is where a trial was stopped

20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT00161993 Jun 2002 → Sep 2003 agammaglobulinemia Baxalta now part of Shire Completed No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as GAMMAGARD S/D “for the first 3 infusions subjects receive GAMMAGARD S/D to ensure a steady-state and to acquire data with a licensed product” NCT00161993
1

NCT00161993